Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Assesment of Disease Activity in Ankylosing Spondylitis: Comparison of Rapid3, Basdai, Basfi, and Asdas Scores in Routine Care.
Cinar1, Muhammet, Yilmaz1, Sedat, Koca2, Suleyman Serdar, Erdem1, Hakan, Pay1, Salih, Yazici3, Yusuf, Simsek1, Ismail
Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey
Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey
Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY
Background/Purpose:
Quantitative assessment of disease outcome in ankylosing spondylitis (AS), as in all other rheumatological conditions, has been a major concern in rheumatology practice. There have been different methods validated and used for monitoring AS patients including, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and recently developed AS disease activity score (ASDAS). It is difficult to distribute multiple questionnaires to different patients in a reception area. A single questionnaire for all patients with rheumatic diseases may present advantages to introduce quantitative measurement into routine care. To this end, routine assessment of patient index data 3 (RAPID3) can be considered as a candidate index, which has been widely used and validated for RA and based on 3 multi-dimensional health assessment questionnaire (MDHAQ) components, patient function, pain and patient global assessment, each scored 0–10 for a total of 0–30. This study was conducted to compare the performance of RAPID3 in comparison with other validated measures in assessing patients with AS.
Methods:
Patients seen consecutively at the rheumatology division of Gulhane School of Medicine, between May 1 and June 25, 2011 completed 3 questionnaires (BASDAI, BASFI, and MDHAQ) at each visit, and their physicians completed physician global assessments on VAS. CRPs were tested on the same date and used to calculate ASDAS-crp scores. Descriptive statistics and Pearson correlation coefficients were calculated for each measure.
Results:
Fifty-one patients [88% male, mean (SD), age: 25.5 (8.4) years, disease duration: 2.8 (4.4) years] completed all assessments. Mean scores for BASDAI, BASFI, ASDAS-crp, and RAPID3 were 5.5 (2.1), 4.1 (2.4), 2.6 (0.9), and 14.5 (5.7) respectively. RAPID3 was strongly correlated with BASDAI, BASFI, and ASDAS-crp (r:0.84, r:072, and r:0.86, p<0.001 for each).
Conclusion:
We found that RAPID3 on an MDHAQ, which had been in use for almost a decade in patients with rheumatoid arthritis, has a strong, positive correlation with the ASDAS-crp, a new composite index to assess disease activity in AS patients. Our results also confirmed the findings of a previous study (1) as showing very good correlation of RAPID3 with the outcome measures of BASDAI and BASFI in AS patients. An outcome measure that can be used in different patient populations may have the additional advantage of being easier to implement in a routine care setting.
References
1.Comparison of rapid3, basdai and basfi in ankylosing spondylitis patients in routine care: RAPID3, composed of patient measures only, is strongly correlated with BASDAI and BASFI [Abstract] Kurtulus, D., Bahadir, C., Swearingen, C.J. & Yazici, Y. 2009;60:510–510, Arthritis & rheumatism
To cite this abstract, please use the following information:
Cinar, Muhammet, Yilmaz, Sedat, Koca, Suleyman Serdar, Erdem, Hakan, Pay, Salih, Yazici, Yusuf, et al; Assesment of Disease Activity in Ankylosing Spondylitis: Comparison of Rapid3, Basdai, Basfi, and Asdas Scores in Routine Care. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :1886
DOI:
